Tag Archives: SARS-CoV-2

Brazilian doctors voluntarily test coronavirus vaccine – World | Instant News


In Brazil, health workers are at the forefront of a coronavirus pandemic in more ways than one, treating patients but also voluntarily testing some of the most promising experimental vaccines.

Brazil is the country with the second highest number of infections and deaths in this pandemic, after the United States, and the virus is still spreading rapidly here.

That is bad news in everything except one: it makes the South American country the ideal testing ground for a potential vaccine against the virus.

The work of guinea pigs falls to medical staff who work in facilities that treat patients infected with the virus, because they are most likely to make contact with them, allowing researchers to conduct controlled trials to see how well they work.

“I want to contribute, and this is my contribution – through science,” said pediatrician Monica Levi, one of 5,000 volunteers in Brazil who helped test one of the most promising vaccines so far, developed by Oxford University and the pharmaceutical company AstraZeneca.

Levi, 53, works at the Special Infectious Disease Clinic and Parasites and Immunizations (Cedipi) in Sao Paulo, the epicenter of the outbreak in Brazil, where more than 2.5 million people have been infected so far, with more than 90,000 deaths.

“Vaccination is my reason. So I have to follow up on my beliefs,” he told AFP.

Last week, Brazil also became the first country to conduct a phase 3 trial of the Chinese vaccine CoronaVac, which was developed by the pharmaceutical company Sinovac Biotech.

Phase 3 clinical trials involve large scale testing in humans, the final step before the vaccine seeks regulatory approval.

Medical workers play a major role in testing the vaccine as well.

“They chose health care professionals because we are always at risk,” Levi said.

Volunteers must be between 18 and 55 years of age, work in patient care roles and not have an underlying medical condition.

Half of the volunteers in the Oxford trial received the vaccine and the other half used a placebo.

But they will only know years from now.

Levi was shot on July 21, and had a headache and cold on the first day, he said.

“But I don’t even know if they gave me a vaccine or a placebo,” he added.

While he waited to find out – and to find out if the vaccine was the way out of a pandemic expected by the whole world – he went to a routine check where the researchers monitored his health.

Scientists around the world are racing to develop and test vaccines for the virus. There are more than 150 projects so far.

But there is no guarantee in a high-risk race.

Brazil has an agreement to make up to 100 million doses of the Oxford vaccine if it proves effective.

But if not, said Levi, “everything will become rubbish.”

.



image source

COVID-19 Early Cases Related to China, Italy, Iran | Instant News


A new study was published in The Lancet Infectious Diseases shows that people with travel links to China, Iran, and Italy accounted for nearly two-thirds of the initial COVID-19 cases in the affected countries.

Data on the initial spread of SARS-CoV-2 is limited and the global epidemiology of confirmed cases outside mainland China is likely to be a point of scientific investigation for some time because complex transmission dynamics.

Investigators publish at Lancet seeks to advance this field of epidemiological research by gathering information in publicly available reports from the pre-pandemic period towards March 10, 2020.

Reports are collected through public health institutions’ websites, press conference transcripts, and social media feeds from government agencies.

Travel history, exposure to other cases, and case characteristics are recorded.

In each of the 99 affected countries outside mainland China, 75 (76%) have recently traveled to the affected countries. According to researchers, 60 (61%) have traveled to China, Italy, or Iran.

Of the 1,200 cases examined with available age or sex information, 874 (73%) were initial cases. The initial case is defined as in the first 100 country records.

Among the 762 initial cases with information on age, the average age was 51 years (IQR 35-63); 25 (3%) of the 762 initial cases occurred in children under 18 years.

In addition, 21 (2%) of the 1,200 cases were among health workers.

Of the 101 clusters identified during the pre-pandemic period, the most commonly identified transmission arrangement is the household (76) [75%]; means 2 · 6 cases per cluster [range 2–7]).

The second and third most common sources of outbreaks appear to be in non-health work environments (14 [14%]; means 4 · 3 cases per cluster [2–14]), and large-scale community meetings (11 [11%]; means 14 · 2 cases per cluster [4–36]).

The researchers point out that although close household contact is a very large source of the initial cluster, clusters in work or community settings tend to be large. This means that the results should not be taken as support or rejection of certain outbreak control policies by the author.

To stay up to date with news and developments in infectious diseases, please List for our weekly bulletin.

.



image source

Monash University Australia develops a new blood test to track the corona virus in 20 minutes: Study | Instant News


Researchers at Monash University in Melbourne have developed new blood tests which they say can be detected positively corona virus (COVID-19) the case took only about 20 minutes and identified if someone had contracted a new virus, a finding that could help the world to reduce corona virus spread through strong contact tracking.

After the US, India has conducted most of the COVID-19 tests, the White House said

Researchers at the university developed a simple agglutination test, an analysis to determine the presence and amount of substances in the blood to detect the presence of increased antibodies in response to SARS-CoV-2 infection.

As part of the study, the research team was able to identify recent COVID-19 cases using 25 microliters of plasma from blood samples, the university said in a statement.

Positive COVID-19 cases cause agglutination or clustering of red blood cells, which are easily identified with the naked eye. The researchers can take positive or negative readings in about 20 minutes, according to the statement.

Fewer COVID-19s retest the Delhi testing strategy

While swab / PCR tests are currently used to identify people who are currently positive with COVID-19, the agglutination test can determine whether someone has just been infected after the infection is resolved – and can potentially be used to detect antibodies that are raised in response to vaccinations to help clinical trials, the researchers said.

Using a simple laboratory set-up, this discovery could see medical practitioners around the world testing up to 200 blood samples per hour, they said.

In some hospitals with high-level diagnostic machines, more than 700 blood samples can be tested every hour – around 16,800 every day.

The research findings can help high-risk countries with population screening, case identification, contact tracing, confirmation of vaccine efficacy during clinical trials and vaccine distribution, the statement said.

A patent for innovation has been filed and researchers are seeking commercial and government support to increase production, he said.

Simon Corrie, a senior chemical engineering lecturer at Monash University, said the findings were of interest to governments and health care teams around the world in a race to stop the spread of COVID-19.

One million milestones: In COVID-19 India number

At present, there are more than 1.41,224,000 confirmed cases of coronavirus worldwide and more than 6.00,000 deaths, according to Johns Hopkins University.

Mr. Corrie said this practice has the potential to be immediately improved for serological testing.

You have reached the limit for free articles this month.

To get full access, please subscribe.

Already have an account? Enter

Show Less Packages

Includes Subscription Benefits

Today’s paper

Find the mobile-friendly version of today’s newspaper in one easy-to-read list.

Faster page

Move smoothly between articles when our page loads instantly.

Unlimited Access

Enjoy reading as many articles as you want without limitations.

Dashboard

A department store to see the latest updates, and manage your preferences.

Personalized recommendations

List of selected articles that fit your interests and tastes.

Briefing

We let you know the latest and most important developments, three times a day.

* Our Digital Subscription Package does not currently include e-paper, crosswords, iPhones, iPad mobile applications and printouts. Our package enhances your reading experience.

.



image source

The China Sinovac phase III trial in Brazil can last only three months 2020-07-10 | Instant News


CAJICA, Colombia and BEIJING – Last week Sinovac Biotech Ltd., from Beijing, announced approval by Anvisa, the Brazilian health oversight body, to begin phase III trials to test the efficacy and safety of the inactive COVID-19 vaccine developed by Sinovac Life Sciences, a Chinese subsidiary, in Latin American countries.

The milestone achieved by Sinovac in Brazil places Chinese biotech among the first developers in the race to get the SARS-CoV-2 vaccine. More than 149 research groups are racing to find solutions to this pandemic.

With Brazil hosting a phase III trial, Sinovac hopes to accelerate its development, because it is trying vaccines in a country that offers a solid regulatory framework, and there is no shortage of volunteers, given the fact that it is the second country with most COVID-19 cases which is confirmed.

“In terms of time, Brazil’s phase III system has been fairly easy and has been well developed since late 2008,” Benny Spiewak, partner at SPLaw, a law firm focusing on life sciences based in Sao Paulo, Brazil, told BioWorld.

“At present, the Ministry of Health and the institutional review board are quite active and they are quite aligned in terms of prioritizing ways to move forward with requests for clinical trial approval,” he explained.

Sinovac partnered with Butantan Institute, from Sao Paulo, Brazil, to submit approval for a phase III trial that tested vaccines, called Coronavac. Butantan is a public research institution that is recognized in Brazil for pioneering work in vaccines.

“This is a pretty brave step, if you ask me,” said Spiewak. “I understand that the structure underlying Butantan is to take an active role in developing vaccines, so having Chinese biopharma joining the effort with Butantan is not real news, because that is the type of entity that Butantan likes.”

According to Anvisa, the vaccine to be tested in Brazil is made from the inactive type SARS-CoV-2. “The proposal provides for testing 9,000 people in the country, in the states of Sao Paulo, Rio Grande do Sul, Minas Gerais, and Paraná, in addition to the Federal District. Volunteer recruitment is the responsibility of the centers that conduct research, “according to Anvisa.

“For this authorization, Anvisa analyzes data from the previous product development stage. “Nonclinical studies on animals are conducted, the results show that vaccines provide acceptable safety,” he explained.

Butantan will begin recruiting 9,000 volunteers for phase III trials this week. Volunteers will be selected from health professionals to directly treat COVID-19 patients.

“The testing process will start on July 20. Participants may not suffer from infections caused by coronavirus, they may not participate in other studies and women cannot become pregnant or plan a pregnancy within the next three months. Another limitation is that they do not have unstable disease or the need for drugs that change the body’s immune response, “Butantan explained.

Analysts such as Spiewak have noted that in the current emergency, phase III trials in Brazil can take less than a semester.

“We look forward to the time frame, for phase III vaccines, at around three to six months, which is quite accelerated, if you compare it to the others,” Spiewak said. “We know that there are certain drugs that take two and a half to five years to complete, and even in phase IV, they can take up to 10 years, because you have ongoing trials,” he added.

The accelerated approval is one of the steps taken by the Brazilian government to deal with a pandemic, which has surpassed 1.7 million cases. Even the country’s president, Jair Bolsonaro, tested positive last week for the virus.

“Unfortunately, we are in a short situation … so, choosing between accelerated reviews and safe and very conservative ones, is something we might not have the privilege of choosing now,” Spiewak said. “Achieving a balance between getting to a safe place and speeding up reviews is a very positive thing.”

According to Spiewak, phase III trials in Brazil are the most structured throughout the world. “The structure is very solid; You don’t have a lot of gray areas to discuss, in terms of post-trial supplies and other things, so this is a very relevant and safe and structured system that we have at the moment in Brazil, “he said.

Chinese trials abroad

Sinovac is not the only Chinese company conducting trials outside the borders of China. Company likes Sinopharm Group, from Shanghai, and Cansino Biologics Inc., from Tianjin China, has observed different jurisdictions to conduct phase III trials.

“We are conducting trials in the UAE and are in talks with other countries. In the future, we can conduct phase III trials in three or four more countries, “said Xiaoming Yang, chairman of Sinopharm, during a Dialogue with the Biotechnology Community webinar, organized by the Hong Kong Stock Exchange on July 6.

For his part, Xuefeng Yu, chairman and CEO at Cansino, confirmed during the same webinar the company’s intention to conduct phase III trials in several different locations throughout the world.

“We hope to move our vaccine candidates to the global phase III trials in the second half of this year, to give them to the world,” he said.

Weidong Yin, chairman, president and CEO of Sinovac, said the company was pleased with the partnership with Butantan. “[This is] “one step further to our commitment to develop vaccines for global use and for our mission to provide vaccines to eliminate human diseases,” he said.

“The approval of phase III clinical trials is a demonstration that the Sinovac and Butantan partnership is an efficient collaboration to move forward offering hope to save lives around the world,” added Dimas Covas, director of the Butantan Institute.

.



image source

‘Disaster’: South Asian scrolls from virus spikes – World | Instant News


Early optimism that South Asia might have avoided the worst damage to the coronavirus pandemic had disappeared when soaring infection rates turned the densely populated region into a global hot spot.

After months of trailing the US and Western Europe, COVID-19 cases have surged across South Asia – home to nearly a quarter of the world’s population – where the virus is wreaking havoc on fragile medical systems and underfunded healthcare institutions pushed to the breaking point

Hospitals that overflowed from Kabul to Dhaka turned away patients suspected of being infected with the virus, the morgue was being overwhelmed by graves and crematoriums struggling to cope, and desperate families sought help for loved ones who were critically ill.

“The situation is a disaster,” Abdur Rob, a senior doctor at the Chittagong General Hospital of Bangladesh, told AFP.

“Patients are dying in ambulances on the road when they are swinging between hospitals looking for a bed (intensive care) or hospital admission.”

Archie Clements, deputy chancellor of the health sciences faculty at Curtin University in Western Australia, said the situation is likely to worsen.

The growth curve “is still in an exponential phase”, Clements said.

“We can head for a greater number of deaths in the coming weeks.”

Worldwide, more than eight million people have been infected by COVID-19 and more than 446,000 people have died, with the virus spreading in South Asia and Latin America.

Simplify locking, increasing cases

A devastating scenario is occurring when a cash-strapped government chooses between enforcing lockdowns or watching low-income families go deeper into poverty, often without a safety net to catch it.

India is the fourth worst country in the world with more than 354,000 confirmed cases – although limited testing means the actual number is likely to be much higher.

The death toll jumped more than 2,000 to 11,900 on Wednesday after Mumbai and New Delhi updated their figures.

The government won praise at the end of March for imposing one of the most stringent closures in the world. But millions of migrant workers do not have jobs and, because they cannot go home, are sometimes detained in overcrowded facilities that increase the risk of transmission.

When the government firmly lifted restrictions, cases increased.

“The problem is that in a country like India, with large-scale poverty and a large migrant community, you cannot expect everyone to take shelter in and out of the storm,” said Michael Kugelman, an analyst from Washington based in Washington. Wilson Center.

In neighboring Pakistan, which has recorded more than 160,000 cases and more than 3,000 deaths, Prime Minister Imran Khan is against national lockdown, saying the country cannot afford it.

Many there chose to ignore social distance guidelines and relaxed provincial locking during last month’s Eid holiday, helping to drive the increase in current cases.

“When the Eid al-Fitr celebration comes, people take the ease of locking as a sign that the disease is over. They flood the market, they go to the cemetery, there is no enforcement (social distance measures),” said Samra Fakhar, a surgeon in the western city Peshawar sea.

Authorities have warned that Pakistan will likely see more than one million cases in July, and the World Health Organization has called for a new closure, an action that Khan has refused.

At an overwhelmed Pakistani hospital, doctors said national leaders were wasting precious initial months to prepare for potential attacks.

“We had the opportunity to prepare for this, but unfortunately it did not happen. Everything will get worse,” said Saeedullah Shah, a doctor with the Pakistan Medical Association task force COVID-19.

“Are we ready for that? Not at all … People will start being rude when they don’t find a bed.”

Further complicating the crisis is limited testing which makes data lower.

Last week, burial figures released by nine government-run graves in the Bangladeshi capital, Dhaka, as well as dozens of smaller graves in a neighboring city, showed at least 1,600 additional deaths in April and May, a major Bengali news website reported.

But health ministry data shows that only 450 people died of COVID-19 in two cities during this period.

Similar anecdotes emerge in conflict-ravaged Afghanistan, which only recognizes more than 26,000 cases and 500 deaths – a number that seems highly improbable for a country that fails to enforce lockdown amid ongoing fighting and where poor poor workers cannot stay at home .

“We have reports of increasing deaths, people burying dead bodies at night,” Kabul governor Mohammad Yakub Haidary said last week, adding that the Afghan capital is thought to have more than one million infected people.

“There is an impending disaster.”

.



image source

US-based Moderna Begins Phase 2 Human Trials for COVID-19 Vaccines | Instant News


Representational pictures

(IANS)

In hopes of COVID-19, Massachusetts-based biotech giant, Moderna, has begun Phase 2 trials for its new coronavirus vaccine, and aims to enroll 600 participants, up from 45 participants in Phase 1 trials.

According to Forbes, Moderna will begin Phase 3 trials in July for its vaccine candidate named mRNA-1273.

“Phase 2 trials can be seen as more important than other phases for several reasons. While Phase 1 trials are used to ensure vaccine safety or treatment in humans, Phase 2 trials measure effectiveness and also provide more data about how safe it is,” the report said on Tuesday.

Based on historical data, the probability of success of a drug moving from Phase 1 clinical trials to Phase 2 is around 63 percent.

Last month, the Moderna mRNA vaccine showed promising results by producing an immune system response in the body against coronavirus.

mRNA-1273 is the mRNA vaccine against SARS-CoV-2 selected by Moderna in collaboration with researchers from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institute. Health (NIH).

Vaccine candidates from NIH and Moderna Inc., including those from Oxford University, have received maximum attention, because more than 100 vaccines are currently in various stages of trial.

US stocks surged as investors watched some encouraging news about a potential coronavirus vaccine. Moderna shares surged nearly 20 percent after the US biotech company announced positive temporary clinical data for a potential coronavirus vaccine on May 18, as the Dow jumped more than 900 points.

Moderna anticipates doses for Phase 3 studies between 25 AUG and 100 AUG and expects the start of Phase 3 trials in July, subject to the finalization of the clinical trial protocol.


The main journalistic mission of the Weather Company is to report the latest weather news, the environment and the importance of science to our lives. This story does not necessarily represent the position of our parent company, IBM.

.



image source

The country of Brazil imposed a curfew in an effort to curb the virus – the World | Instant News


Authorities imposed a curfew on Wednesday in all regions of the Brazilian state of Bahia in an effort to slow the spread of the corona virus in the country’s northeast.

With the virus still spreading rapidly in Brazil – the country with the second highest caseload, after the United States – Governor Bahia Rui Costa issued 6:00 p.m. to 5:00 p.m. curfew for the 19 southernmost cities in the state, effective until 9 June

He also ordered the closure of all but important businesses and services in the same zone, the state government said.

“It is necessary and urgent to impose greater limits, after recording very high [infection] tariffs “in the area, Costa said in announcing the steps.

“If we don’t act, we can see an explosion of cases and an explosion of bed requests in the intensive care unit, which we won’t be able to meet.”

The alternative, he said, was “a large number of deaths” in Bahia, which has recorded more than 21,000 cases and 700 deaths so far.

The area affected by the decree is on the border between the two regions of Brazil most badly hit by the new corona virus: southeast and northeast.

The outbreak in Brazil begins in the southeast, the country’s rich business and industrial corridor.

The region, which includes Sao Paulo and Rio de Janeiro, remains the hardest hit, with more than 200,000 cases and nearly 15,000 deaths.

But the northeast, the poorest region in Brazil, has emerged as the second worst, with almost 195,000 cases and 10,000 deaths.

Health officials believe the outbreak in the northeast is partly driven by poor migrant workers from areas who have returned home after losing their jobs in the southeast due to the closure of virus-related businesses and permanent measures at home.

Brazil as a whole has now registered more than 555,000 cases and 31,000 deaths.

Experts say testing means the actual figure may be much higher.

President Jair Bolsonaro is a vocal critic of the steps to stay at home, arguing they do not need to hurt Latin America’s largest economy.

Right-wing leaders have urged businesses to “wage war” on such measures from state authorities.

If you want to help in the fight against COVID-19, we have compiled a list of the latest community initiatives designed to help medical workers and low-income people in this article. Link: [UPDATED] Anti-COVID-19 Initiative: Helping Indonesia fight the plague

.



image source

Is Coronavirus Really Losing Potential in Italy? What you need to know | Instant News


There are claims from doctors in Italy that Covid-19 coronavirus might lose potential in Italy. But as most horror films might teach you, don’t assume that the threat has subsided until you are truly, positively, truly convinced that it happened.

This Reuters The video covered this claim by Dr. Alberto Zangrillo, who is the head of the San Raffaele Hospital in Milan, Italy:

As Reuters report indicatedZangrillo said that “in reality, the virus clinically no longer exists in Italy,” and that “the swabs carried out over the past 10 days showed a quantitative viral load that was really very small compared to what was done a month or two months ago. “Hmm,” clinically no more, “is a pretty bold claim. Did he check everyone in Italy for symptoms or viruses to confirm this statement? That will require a lot of swabs.

The WHO response to Zangrillo’s comments is the same as saying “what?” Just listen to what Mike Ryan, MD, MPH, Executive Director of the World Health Organization (WHO) Emergency Health Program at a press conference today:

As you can see, Ryan warns that “we must be very careful that we do not create the feeling that suddenly the virus has decided to become less pathogenic. That’s not the problem at all. “He stressed that the Covid-19 coronavirus is still a” killer virus. ”

AKate Kelland and Emilio Parodi reported Reuters, WHO’s Technical and Epidemiology Chief Maria Van Kerkhove said, “In terms of transmission, it has not changed, in terms of severity, it has not changed.”

Viruses such as Covid-19 coronavirus are not like Viagra. They do not automatically lose potential over time. Yes, there is a possibility that a less dangerous version of the virus could appear and eventually become more common than the initial version. There is also the possibility of “uh-oh” that a more dangerous version can appear. Both of these possibilities tend not to occur overnight.

Can moving closer to Summer potentially cause a decrease in virus activity? Of course, if Coona-19 coronavirus transmission shows the same type of seasonal fluctuation as the flu virus. I discussed this possibility before Forbes. It is still unclear whether this will happen. However, before making a bold statement about losing potential viruses, as they say with science and whiskey, you must have enough evidence.

This type of evidence only arises after extensive testing and supervision from time to time and in many locations. Testing in one hospital or even several hospitals over a ten day period will not tell you the whole story. It’s like going to Pizza Hut and using your visit there to make conclusions about pizza in general. Remember, not all pizzas are filled with cheese. Likewise, the number of viruses in swab testing at a hospital or even a group of hospitals does not always represent what is happening throughout the country.

Instead, you have to get a large enough sample over a long period of time to really understand what’s happening throughout the country and ensure that it’s not just a momentary decline. Extension of time means more than 10 days, which is still less than what might be the virus incubation period. For example, what if the virus spreads more among people who are less fortunate or more socially isolated who may not have ready access to health care and thus do not need to be seen by a doctor?

Also, keep in mind that Italy has indeed closed everything for a while with aggressive social distancing measures. So all of those efforts might reduce the transmission of the virus at least a little. Will the reopening of society in Italy lead to a bad sequel to what was a bad first installment, a kind of film Growing Up 2 after the first one Adult film? Can the sequel come in Autumn? It’s too early to say.

The situation in Italy is indeed bearable. More real scientific evidence is needed and reviewed by colleagues before concluding something new about the potential of the virus. Even if some changes occur in Italy, that doesn’t always mean that the same thing will eventually happen elsewhere. What happened in Italy could still remain in Italy.

.



image source

The mob attacked the Karachi Civil Hospital after the death of a coronavirus patient | Instant News


The doctor has requested the deployment of security guards at the hospital

->

PICTURE OF REPRESENTATIVE

PICTURE OF REPRESENTATIVE
PHOTO: AYESHA MIR / EXPRESS

KARACHI: Crowds rushed to Karachi Civil Hospital on Friday night after a coronavirus patient died during treatment and attacked on-duty medical staff.

At least 70 people entered the hospital and took the bodies of the deceased from the emergency room and also harassed and attacked the medical officers on duty, according to hospital management.

Doctors claim that patient swabs are taken according to standard operating procedures (SOP).

MS Hospital Dr. Khadim Qureshi confirmed the incident The Express Tribune that the police were asked to file an FIR against those involved in the attack.

“Doctors demand security. “It’s difficult for them to work in situations like this,” he added.

Another doctor who was on duty at the time, said the incident occurred at around 11 pm. He and other doctors on duty were also tortured and tortured. “This is the third time in a week,” he said.

The doctor stated that the police, who were stationed outside the hospital gates, did not help the medical staff. No arrests have been made yet and doctors have requested the deployment of Sindh Rangers for safety.

.



image source

Brazil stands beside hydroxychloroquine despite WHO – World | Instant News


The Brazilian Ministry of Health said on Monday that it would not change its recommendation to treat coronavirus with hydroxychloroquine, even though the World Health Organization decided to postpone the trial of the drug due to safety concerns.

Like his US counterpart Donald Trump, Brazilian President Jair Bolsonaro has been touting the benefits of suspected chloroquine hydroxy and related drug, chloroquine, against the new corona virus.

Research, however, has questioned their safety and efficacy against the disease, including one published Friday in the leading medical journal The Lancet which found that the drugs actually increased the risk of death.

That led WHO to delay clinical trials of chloroquine hydroxide worldwide as a treatment for COVID-19 on Monday.

“We remain calm and there will be no changes” to Brazilian guidelines issued last week, health ministry official Mayra Pinheiro told a news conference.

The guidelines recommend doctors in the public health system to prescribe chloroquine or chloroquine hydroxy from the onset of symptoms of COVID-19.

It was issued shortly after the resignation of former health minister Nelson Teich, who reportedly stopped at the urging of Bolsonaro to push for drugs despite the lack of hard evidence.

He is Brazil’s second health minister in less than a month.

Brazil, the Latin American country hardest hit by the pandemic, has emerged as the last flashpoint, with almost 375,000 cases – the second highest in the world, after the United States – and more than 23,000 deaths.

Experts say testing means the actual figure may be much higher.

Hydroxychloroquine is usually used to treat autoimmune diseases, while chloroquine is commonly used to fight malaria.

Preliminary studies in China and France have produced hopes that drugs might be effective against the new corona virus.

That makes the government buy it in large quantities. Trump even said last week that he used hydroxychloroquine as a preventative measure, even though he said on Sunday that he had completed his treatment.

Pinheiro questioned the Lancet study, which analyzed the medical records of 96,000 patients in hundreds of hospitals.

“It was not a clinical trial, it was only a collection of data collected from various countries, and it did not meet the methodological study criteria for reference in any country in the world, including Brazil,” he said. the word.

If you want to help in the fight against COVID-19, we have compiled a list of the latest community initiatives designed to help medical workers and low-income people in this article. Link: [UPDATED] Anti-COVID-19 Initiative: Helping Indonesia fight the plague

.



image source